vs

Side-by-side financial comparison of Hippo Holdings Inc. (HIPO) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

Hippo Holdings Inc. is the larger business by last-quarter revenue ($120.4M vs $69.8M, roughly 1.7× RIGEL PHARMACEUTICALS INC). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs 5.0%, a 379.1% gap on every dollar of revenue. On growth, RIGEL PHARMACEUTICALS INC posted the faster year-over-year revenue change (21.2% vs 18.2%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 18.9%).

Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

HIPO vs RIGL — Head-to-Head

Bigger by revenue
HIPO
HIPO
1.7× larger
HIPO
$120.4M
$69.8M
RIGL
Growing faster (revenue YoY)
RIGL
RIGL
+3.0% gap
RIGL
21.2%
18.2%
HIPO
Higher net margin
RIGL
RIGL
379.1% more per $
RIGL
384.0%
5.0%
HIPO
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
18.9%
HIPO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HIPO
HIPO
RIGL
RIGL
Revenue
$120.4M
$69.8M
Net Profit
$6.0M
$268.1M
Gross Margin
91.5%
Operating Margin
5.6%
33.2%
Net Margin
5.0%
384.0%
Revenue YoY
18.2%
21.2%
Net Profit YoY
-86.4%
1769.2%
EPS (diluted)
$0.31
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HIPO
HIPO
RIGL
RIGL
Q4 25
$120.4M
$69.8M
Q3 25
$120.6M
$69.5M
Q2 25
$117.3M
$101.7M
Q1 25
$110.3M
$53.3M
Q4 24
$101.9M
$57.6M
Q3 24
$95.5M
$55.3M
Q2 24
$89.6M
$36.8M
Q1 24
$85.1M
$29.5M
Net Profit
HIPO
HIPO
RIGL
RIGL
Q4 25
$6.0M
$268.1M
Q3 25
$98.1M
$27.9M
Q2 25
$1.3M
$59.6M
Q1 25
$-47.7M
$11.4M
Q4 24
$44.2M
$14.3M
Q3 24
$-8.5M
$12.4M
Q2 24
$-40.5M
$-1.0M
Q1 24
$-35.7M
$-8.2M
Gross Margin
HIPO
HIPO
RIGL
RIGL
Q4 25
91.5%
Q3 25
93.2%
Q2 25
95.6%
Q1 25
91.7%
Q4 24
89.9%
Q3 24
85.5%
Q2 24
92.4%
Q1 24
93.1%
Operating Margin
HIPO
HIPO
RIGL
RIGL
Q4 25
5.6%
33.2%
Q3 25
81.3%
40.9%
Q2 25
3.4%
60.1%
Q1 25
-41.3%
23.9%
Q4 24
46.3%
28.9%
Q3 24
-5.4%
25.4%
Q2 24
-40.7%
1.2%
Q1 24
-38.7%
-23.6%
Net Margin
HIPO
HIPO
RIGL
RIGL
Q4 25
5.0%
384.0%
Q3 25
81.3%
40.2%
Q2 25
1.1%
58.6%
Q1 25
-43.2%
21.5%
Q4 24
43.4%
24.9%
Q3 24
-8.9%
22.5%
Q2 24
-45.2%
-2.8%
Q1 24
-42.0%
-27.9%
EPS (diluted)
HIPO
HIPO
RIGL
RIGL
Q4 25
$0.31
$14.11
Q3 25
$3.77
$1.46
Q2 25
$0.05
$3.28
Q1 25
$-1.91
$0.63
Q4 24
$1.81
$0.82
Q3 24
$-0.34
$0.70
Q2 24
$-1.64
$-0.06
Q1 24
$-1.47
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HIPO
HIPO
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$218.3M
$155.0M
Total DebtLower is stronger
$52.5M
Stockholders' EquityBook value
$436.1M
$391.5M
Total Assets
$1.9B
$513.6M
Debt / EquityLower = less leverage
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HIPO
HIPO
RIGL
RIGL
Q4 25
$218.3M
$155.0M
Q3 25
$247.7M
$137.1M
Q2 25
$198.9M
$108.4M
Q1 25
$140.9M
$77.1M
Q4 24
$197.6M
$77.3M
Q3 24
$191.2M
$61.1M
Q2 24
$175.9M
$49.1M
Q1 24
$223.4M
$49.5M
Total Debt
HIPO
HIPO
RIGL
RIGL
Q4 25
$52.5M
Q3 25
$60.0M
Q2 25
$60.0M
Q1 25
$60.0M
Q4 24
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Q1 24
$60.0M
Stockholders' Equity
HIPO
HIPO
RIGL
RIGL
Q4 25
$436.1M
$391.5M
Q3 25
$421.5M
$117.6M
Q2 25
$332.5M
$81.9M
Q1 25
$322.8M
$18.6M
Q4 24
$362.1M
$3.3M
Q3 24
$326.4M
$-14.6M
Q2 24
$322.6M
$-29.9M
Q1 24
$351.2M
$-31.7M
Total Assets
HIPO
HIPO
RIGL
RIGL
Q4 25
$1.9B
$513.6M
Q3 25
$1.9B
$242.5M
Q2 25
$1.7B
$206.7M
Q1 25
$1.5B
$176.0M
Q4 24
$1.5B
$164.0M
Q3 24
$1.5B
$139.4M
Q2 24
$1.5B
$128.4M
Q1 24
$1.5B
$126.5M
Debt / Equity
HIPO
HIPO
RIGL
RIGL
Q4 25
0.13×
Q3 25
0.51×
Q2 25
0.73×
Q1 25
3.23×
Q4 24
18.25×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HIPO
HIPO
RIGL
RIGL
Operating Cash FlowLast quarter
$9.2M
$22.0M
Free Cash FlowOCF − Capex
$9.1M
FCF MarginFCF / Revenue
7.6%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.53×
0.08×
TTM Free Cash FlowTrailing 4 quarters
$14.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HIPO
HIPO
RIGL
RIGL
Q4 25
$9.2M
$22.0M
Q3 25
$16.9M
$24.0M
Q2 25
$24.7M
$30.5M
Q1 25
$-35.6M
$-893.0K
Q4 24
$47.5M
$14.5M
Q3 24
$46.8M
$21.7M
Q2 24
$-10.6M
$302.0K
Q1 24
$17.7M
$-5.0M
Free Cash Flow
HIPO
HIPO
RIGL
RIGL
Q4 25
$9.1M
Q3 25
$16.8M
Q2 25
$24.6M
Q1 25
$-35.7M
Q4 24
$47.2M
Q3 24
Q2 24
$-10.7M
Q1 24
$17.6M
FCF Margin
HIPO
HIPO
RIGL
RIGL
Q4 25
7.6%
Q3 25
13.9%
Q2 25
21.0%
Q1 25
-32.4%
Q4 24
46.3%
Q3 24
Q2 24
-11.9%
Q1 24
20.7%
Capex Intensity
HIPO
HIPO
RIGL
RIGL
Q4 25
0.1%
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.3%
Q3 24
0.0%
Q2 24
0.1%
Q1 24
0.1%
Cash Conversion
HIPO
HIPO
RIGL
RIGL
Q4 25
1.53×
0.08×
Q3 25
0.17×
0.86×
Q2 25
19.00×
0.51×
Q1 25
-0.08×
Q4 24
1.07×
1.01×
Q3 24
1.75×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons